Testing a drug in a new population of critically ill patients has to be done cautiously (first, do no harm) and with the exception of the one patient who had a second stroke, it appears the drug was well tolerated. N=6 with no control group could never have been expected to prove any great efficacy. The best news about the trial is that it appears to show no reason not to progress further. That means more and bigger trials. Hurry up and wait, but AIS and afamelanotide is still a live project.
Testing a drug in a new population of critically ill patients...
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.28 |
Change
-0.250(1.85%) |
Mkt cap ! $664.8M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.62 | $13.25 | $1.157M | 86.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 227 | $13.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.42 | 228 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |